Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$52 Mln
P/E Ratio
--
P/B Ratio
3.91
Industry P/E
--
Debt to Equity
0.08
ROE
-1.47 %
ROCE
-140.66 %
Div. Yield
0 %
Book Value
0.47
EPS
-0.76
CFO
$-21.56 Mln
EBITDA
$-26.99 Mln
Net Profit
$-50.16 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Immix Biopharma Inc (IMMX)
| -8.18 | 18.82 | -1.46 | -5.16 | 14.10 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Immix Biopharma Inc (IMMX)
| -67.91 | 202.18 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,315.11 | 21.27 | 23.13 | |
| 306.35 | 8,705.27 | 22.77 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead... product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California. Read more
Co-Founder, CEO & Chairman
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Co-Founder, CEO & Chairman
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Headquarters
Los Angeles, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Immix Biopharma Inc (IMMX) stood at $ 23 Mln as on 31-Dec-24
The share price of Immix Biopharma Inc (IMMX) is $2.02 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Immix Biopharma Inc (IMMX) has given a return of 14.1% in the last 3 years.
Immix Biopharma Inc (IMMX) has a market capitalisation of $ 52 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Immix Biopharma Inc (IMMX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immix Biopharma Inc (IMMX) and enter the required number of quantities and click on buy to purchase the shares of Immix Biopharma Inc (IMMX).
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
The CEO & director of Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.. is Immix Biopharma Inc (IMMX), and CFO & Sr. VP is Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D..
There is no promoter pledging in Immix Biopharma Inc (IMMX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Immix Biopharma Inc (IMMX) | Ratios |
|---|---|
|
Return on equity(%)
|
-145.76
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Immix Biopharma Inc (IMMX) was $0 Mln.
$0.08
(
